Tendinitis - Pipeline Insight, 2021

Tendinitis - Pipeline Insight, 2021

  • May 2021 •
  • 60 pages •
  • Report ID: 6068381 •
  • Format: PDF
“Tendinitis - Pipeline Insight, 2021,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Tendinitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Tendinitis Understanding

Tendinitis: Overview

Tendinitis is an inflammation of a tendon, a group of sturdy fibers that connects a muscle to the nearby bone. Another commonly used term for tendinitis is tendinopathy. Tendinitis is generally caused by injury, trauma, or overuse of a joint. Tendinitis may be referred to by a more specific description depending on the location where it occurs, such as Achilles tendinitis or tennis elbow. The elbows, heel, shoulder and wrist are common locations for tendinitis. Tendinitis is treated with rest along with medications to relieve pain and reduce inflammation. Physical therapy can be helpful to improve muscle strength and enhance healing. In some cases, surgery will need to be performed to repair tendon damage.

"Tendinitis - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Tendinitis pipeline landscape is provided which includes the disease overview and Tendinitis treatment guidelines. The assessment part of the report embraces, in depth Tendinitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Tendinitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Tendinitis R&D. The therapies under development are focused on novel approaches to treat/improve Tendinitis.

Tendinitis Emerging Drugs Chapters
This segment of the Tendinitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Tendinitis Emerging Drugs
• SI-613: Seikagaku Corporation
SI-613 is a formulation in which hyaluronic acid and a non-steroidal anti-inflammatory drug (NSAID) are chemically bound using Seikagaku’s own proprietary technology. SI-613 was designed to provide pain relief and anti-inflammatory effect by sustained release of NSAID, and the joint function improving effect by hyaluronic acid. It is expected to provide prompt and sustained relief of the severe pain and inflammation associated with osteoarthritis and enthesopathy. The drug is currently in phase II of clinical trials for the treatment of tendinitis.

• MP1032: MetrioPharm
MP1032’s mode of action – to accelerate the healing process – allows for the use of MP1032 as a therapeutic for tendinitis before a tendinosis develops. In addition, MP1032 could accelerate the repair of already damaged tendons and thus also shorten the duration of tendinosis treatments. The drug is currently in phase I of clinical trials for the treatment of tendinitis.
Further product details are provided in the report……..

Tendinitis: Therapeutic Assessment
This segment of the report provides insights about the different Tendinitis drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Tendinitis
There are approx. 4+ key companies which are developing the therapies for Tendinitis. The companies which have their Tendinitis drug candidates in the most advanced stage, i.e. phase II include, Seikagaku Corporation.

• Phases
This report covers around 4+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration
Tendinitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• intravitreal
• Subretinal
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Tendinitis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Tendinitis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Tendinitis drugs.

Tendinitis Report Insights
• Tendinitis Pipeline Analysis

• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Tendinitis Report Assessment
• Pipeline Product Profiles

• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Tendinitis drugs?
• How many Tendinitis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Tendinitis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Tendinitis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Tendinitis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players
• Seikagaku Corporation
• MetrioPharm
• MiMedx
• Zhejiang Xingyue Biotechnology Co., Ltd.
• R3 Stem Cell
• Dobecure
• Causeway Therapeutics

Key Products
• SI-613
• MP 1032
• Ultrasound-guided pure platelet-rich-plasma (P-PRP) injection
• CWT 001